All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The Lupus Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your Lupus Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.



Corticosteroids provide rapid symptom relief. The medium- to long-term aim should be to reduce the daily dose to ≤7.5 mg/day prednisone equivalent or to discontinue, as long-term use can be detrimental (irreversible organ damage). Pulsed IV methylprednisolone of various doses and early initiation of immunosuppressive therapy may reduce risks by enabling use of a lower starting dose/faster tapering, and eventual discontinuation of glucocorticoids.

Save to your areas of interest